PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$36.64 USD
+0.48 (1.33%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $36.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Income Statements
Fiscal Year end for PTC Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 938 | 699 | 539 | 381 | 307 |
Cost Of Goods | 65 | 45 | 32 | 19 | 12 |
Gross Profit | 872 | 654 | 506 | 362 | 295 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,312 | 1,102 | 881 | 794 | 536 |
Income After Depreciation & Amortization | -440 | -447 | -374 | -432 | -241 |
Non-Operating Income | -127 | -49 | -58 | 85 | 14 |
Interest Expense | 129 | 91 | 86 | 56 | 12 |
Pretax Income | -696 | -587 | -518 | -403 | -240 |
Income Taxes | -70 | -28 | 6 | 35 | 12 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -627 | -559 | -524 | -438 | -252 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -627 | -559 | -524 | -438 | -252 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 15 | -282 | -303 | -345 | -210 |
Depreciation & Amortization (Cash Flow) | 454 | 166 | 71 | 86 | 31 |
Income After Depreciation & Amortization | -440 | -447 | -374 | -432 | -241 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 74.84 | 71.73 | 70.47 | 66.03 | 58.86 |
Diluted EPS Before Non-Recurring Items | -3.62 | -7.79 | -7.43 | -6.50 | -3.45 |
Diluted Net EPS (GAAP) | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 |
Fiscal Year end for PTC Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 186.70 | 210.12 | 307.06 | 196.58 | 213.81 |
Cost Of Goods | 15.53 | 14.74 | 29.12 | 9.49 | 12.73 |
Gross Profit | 171.18 | 195.38 | 277.94 | 187.08 | 201.08 |
SG&A, R&D, and Dept/Amort Expenses | 211.40 | 240.83 | 272.11 | 305.25 | 410.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | -40.22 | -45.45 | 5.83 | -118.17 | -209.54 |
Non-Operating Income | -2.03 | 1.59 | -118.60 | -20.27 | 1.48 |
Interest Expense | 43.49 | 40.83 | 44.27 | 28.16 | 29.42 |
Pretax Income | -85.73 | -84.70 | -157.05 | -166.59 | -237.48 |
Income Taxes | 13.45 | 6.88 | -1.26 | -33.62 | -38.60 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -99.18 | -91.58 | -155.79 | -132.97 | -198.88 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -99.18 | -91.58 | -155.79 | -132.97 | -198.88 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 76.73 | 76.50 | 75.49 | 75.38 | 74.73 |
Diluted EPS Before Non-Recurring Items | -1.16 | -1.20 | -0.24 | -1.76 | -2.66 |
Diluted Net EPS (GAAP) | -1.29 | -1.20 | -2.07 | -1.76 | -2.66 |